Definitive Healthcare Corp. (NASDAQ:DH) Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC decreased its position in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 88.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 266,719 shares of the company’s stock after selling 1,991,131 shares during the quarter. Clearbridge Investments LLC’s holdings in Definitive Healthcare were worth $2,152,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DH. Tower Research Capital LLC TRC lifted its holdings in shares of Definitive Healthcare by 599.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after purchasing an additional 4,959 shares during the period. Norden Group LLC purchased a new stake in shares of Definitive Healthcare in the first quarter valued at approximately $83,000. Berry Wealth Group LP purchased a new stake in shares of Definitive Healthcare in the first quarter valued at approximately $99,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Definitive Healthcare in the first quarter valued at approximately $120,000. Finally, Reynders McVeigh Capital Management LLC acquired a new stake in shares of Definitive Healthcare in the fourth quarter worth approximately $129,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Analysts Set New Price Targets

DH has been the topic of a number of recent research reports. Morgan Stanley lowered Definitive Healthcare from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $11.50 to $9.00 in a research note on Wednesday, May 8th. Canaccord Genuity Group decreased their price target on Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Definitive Healthcare in a research note on Tuesday, May 14th. Barclays decreased their price target on Definitive Healthcare from $11.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 9th. Finally, Stifel Nicolaus cut their price objective on Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Eight investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.56.

Definitive Healthcare Stock Up 1.9 %

Definitive Healthcare stock traded up $0.11 during mid-day trading on Thursday, reaching $5.95. 8,666 shares of the company were exchanged, compared to its average volume of 691,082. Definitive Healthcare Corp. has a twelve month low of $4.38 and a twelve month high of $12.37. The firm’s 50-day simple moving average is $5.52 and its two-hundred day simple moving average is $7.25. The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The company had revenue of $63.48 million for the quarter, compared to analyst estimates of $64.00 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. Research analysts forecast that Definitive Healthcare Corp. will post 0.1 earnings per share for the current fiscal year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.